Valued at USD 312.62 million in 2025, the Residual DNA Testing Market is expected to reach USD 329.66 million in 2026 and USD 519.69 million by 2034, expanding at a CAGR of 5.9% during the forecast period 2026–2034. Rising biologics manufacturing and vaccine manufacturing, along with increasing regulatory focus on product safety, are the principal drivers. North America led in 2025 with a...

The increasing demand for residual host cell DNA testing, rapid adoption of the digital PCR testing market, and expansion of biologics testing services are transforming quality assurance processes within the biopharmaceutical industry. As the production of biologics, vaccines, gene therapies, and advanced therapeutic products continues to expand, ensuring product safety and...